Skip to main content
Log in

Does the roadmap show the way to cost effectiveness in Hep B?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. Lui YYN, Tsoi KKF, Wong VWS, Chan HLY.Is the roadmap model cost-effective in the era of tenofovir in the treatment of chronic hepatitis B virus infection? 44th Annual Meeting of the European Association for the Study of the Liver: abstr. 802, 25 Apr 2009. Available from: URL: http://www2.kenes.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Does the roadmap show the way to cost effectiveness in Hep B?. Pharmacoecon. Outcomes News 578, 5 (2009). https://doi.org/10.2165/00151234-200905780-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905780-00010

Keywords

Navigation